Fisher Asset Management LLC Takes $1.01 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Fisher Asset Management LLC purchased a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 62,372 shares of the company's stock, valued at approximately $1,006,000. Fisher Asset Management LLC owned 0.08% of Deciphera Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C increased its stake in shares of Deciphera Pharmaceuticals by 2.8% in the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company's stock valued at $87,738,000 after buying an additional 190,580 shares during the period. Armistice Capital LLC grew its stake in Deciphera Pharmaceuticals by 1.1% during the third quarter. Armistice Capital LLC now owns 4,612,000 shares of the company's stock worth $58,665,000 after purchasing an additional 52,000 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Deciphera Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 501,585 shares of the company's stock worth $6,380,000 after purchasing an additional 8,325 shares during the period. Deutsche Bank AG grew its stake in Deciphera Pharmaceuticals by 36.7% during the third quarter. Deutsche Bank AG now owns 254,671 shares of the company's stock worth $3,239,000 after purchasing an additional 68,435 shares during the period. Finally, Schonfeld Strategic Advisors LLC grew its stake in Deciphera Pharmaceuticals by 2.6% during the third quarter. Schonfeld Strategic Advisors LLC now owns 232,900 shares of the company's stock worth $2,962,000 after purchasing an additional 5,947 shares during the period. Institutional investors and hedge funds own 70.96% of the company's stock.

Deciphera Pharmaceuticals Stock Down 0.0 %

Shares of DCPH stock traded down $0.01 during trading hours on Friday, reaching $25.36. The company had a trading volume of 1,795,414 shares, compared to its average volume of 3,625,582. Deciphera Pharmaceuticals, Inc. has a 12 month low of $9.90 and a 12 month high of $25.55. The business has a fifty day simple moving average of $17.41 and a 200-day simple moving average of $15.32.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) last posted its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. During the same quarter last year, the company earned ($0.60) earnings per share. The company's revenue for the quarter was up 32.9% on a year-over-year basis. Sell-side analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on DCPH shares. Jonestrading reaffirmed a "hold" rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a research note on Monday, April 29th. Guggenheim reaffirmed a "neutral" rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday, April 30th. JMP Securities reiterated a "market perform" rating on shares of Deciphera Pharmaceuticals in a report on Tuesday, April 30th. Stifel Nicolaus increased their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, February 7th. Finally, Barclays upgraded Deciphera Pharmaceuticals from an "underweight" rating to an "equal weight" rating and increased their price target for the stock from $9.00 to $26.00 in a report on Tuesday, April 30th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $24.17.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.